Chai Discovery
AI-driven biotech for drug discovery
CORE INFO
Chai Discovery is a biotechnology company that leverages artificial intelligence to design new molecules for innovative medicines, collaborating with leading pharmaceutical firms to accelerate drug discovery.
- Chai Discovery raised $400 million in a Series C funding round led by Index Ventures, valuing the company at $3.8 billion.biospace.com
- The company's flagship AI model, Chai-2, achieved a 20% experimental hit rate in de novo antibody design, significantly outperforming previous methods.research.contrary.com
- Chai Discovery has established partnerships with major pharmaceutical companies, including Eli Lilly, Pfizer, and Novartis.forbes.com
WHY WE WOULD WORK AT CHAI DISCOVERY
Innovative Drug Discovery
Join a team revolutionizing drug discovery with AI-driven solutions, like the Chai-2 model, achieving a 20% hit rate in antibody design.
Cutting-Edge Technology
Work with advanced generative AI models that predict biochemical interactions, pushing the boundaries of molecular design in biotechnology.
Collaborate with Giants
Partner with leading pharmaceutical companies such as Eli Lilly and Pfizer, directly impacting the future of medicine.
Rapid Growth Potential
Be part of a fast-growing startup valued at $3.8 billion, with over $600 million in funding, offering significant career advancement opportunities.
Mission-Driven Culture
Contribute to a mission focused on designing new medicines with precision and speed, making a real difference in patients' lives.
Dynamic Work Environment
Experience a collaborative culture that fosters innovation and creativity, where every team member's ideas are valued and encouraged.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
NOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICGROWTH TACTICS
COMPETITIVE ADVANTAGE
PRODUCT AND TECH
Chai-2 AI Model
Chai-2 is Chai Discovery's flagship AI model that specializes in de novo antibody design, achieving a remarkable 20% experimental hit rate, significantly outperforming previous computational methods.
AI-Driven Drug Discovery
Chai Discovery leverages artificial intelligence to accelerate the drug discovery process, providing innovative solutions that enhance the efficiency and effectiveness of designing new medicines.
Collaborative Partnerships
The company partners with leading pharmaceutical firms like Eli Lilly and Pfizer to integrate AI-driven solutions into their drug discovery workflows, fostering innovation in the life sciences sector.
Generative AI Technology
Chai Discovery specializes in generative AI models that learn biological structures and interactions, enabling the computational design of new molecules for novel therapeutics.
Biotechnology Applications
The company operates at the intersection of biotechnology and artificial intelligence, focusing on developing advanced methodologies for molecular design and antibody discovery.